Drug Trial Radar · NCT06717360
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Sep 30, 2024
Primary completion
Jul 10, 2025
Study completion May 12, 2026
Sponsor
- Lead sponsor
- Ahn-Gook Pharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia
Conditions
- Hypercholesterolemia
Interventions
AG2304TDrug
AG2304T, QD, PO
AG2304RDrug
AG2304R, QD, PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-C levelTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AhnGook
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.